open access

Vol 3, No 2 (2018)
REVIEW
Published online: 2017-11-13
Get Citation

Jak skutecznie leczyć wysiękową postać zwyrodnienia plamki związanego z wiekiem według schematu PRN? Rola biomarkerów widocznych w obrazach optycznej koherentnej tomografii

Anna Matysik-Woźniak, Marek Rękas, Robert Rejdak
DOI: 10.5603/OJ.2018.0030
·
Ophthalmol J 2018;3(2):47-57.

open access

Vol 3, No 2 (2018)
REVIEW
Published online: 2017-11-13

Abstract

Optymalizacja leczenia uwzględniająca indywidualny przebieg choroby nadal pozostaje jednym z podstawowych problemow w leczeniu wysiękowej postaci zwyrodnienia plamki związanego z wiekiem (AMD). W niniejszej pracy autorzy zawarli wskazowki, ktore mogą być pomocne podczas terapii według schematu pro-re-nata (PRN). Obecnie ma on zastosowanie u większości pacjentow będących w programie lekowym. Jednym z podstawowych problemow jest właściwa ocena aktywności choroby, ktora stanowi podstawę decyzji o wykonaniu kolejnej iniekcji lekow blokujących czynnik wzrostu środbłonka naczyń (anty-VEGF). Określenie parametrow, takich jak stan fotoreceptorow czy nabłonka barwnikowego siatkowki (RPE), lokalizacja płynu, zachowanie prawidłowego układu warstw siatkowki, obecność schorzeń pogranicza szklistkowo-siatkowkowego, wpływa na ocenę stanu klinicznego i rokowanie chorych.

Abstract

Optymalizacja leczenia uwzględniająca indywidualny przebieg choroby nadal pozostaje jednym z podstawowych problemow w leczeniu wysiękowej postaci zwyrodnienia plamki związanego z wiekiem (AMD). W niniejszej pracy autorzy zawarli wskazowki, ktore mogą być pomocne podczas terapii według schematu pro-re-nata (PRN). Obecnie ma on zastosowanie u większości pacjentow będących w programie lekowym. Jednym z podstawowych problemow jest właściwa ocena aktywności choroby, ktora stanowi podstawę decyzji o wykonaniu kolejnej iniekcji lekow blokujących czynnik wzrostu środbłonka naczyń (anty-VEGF). Określenie parametrow, takich jak stan fotoreceptorow czy nabłonka barwnikowego siatkowki (RPE), lokalizacja płynu, zachowanie prawidłowego układu warstw siatkowki, obecność schorzeń pogranicza szklistkowo-siatkowkowego, wpływa na ocenę stanu klinicznego i rokowanie chorych.

Get Citation

Keywords

zwyrodnienie plamki związane z wiekiem, aflibercept, ranibizumab, schemat PRN, biomarkery, optyczna koherentna tomografia

About this article
Title

Jak skutecznie leczyć wysiękową postać zwyrodnienia plamki związanego z wiekiem według schematu PRN? Rola biomarkerów widocznych w obrazach optycznej koherentnej tomografii

Journal

Ophthalmology Journal

Issue

Vol 3, No 2 (2018)

Pages

47-57

Published online

2017-11-13

DOI

10.5603/OJ.2018.0030

Bibliographic record

Ophthalmol J 2018;3(2):47-57.

Keywords

zwyrodnienie plamki związane z wiekiem
aflibercept
ranibizumab
schemat PRN
biomarkery
optyczna koherentna tomografia

Authors

Anna Matysik-Woźniak
Marek Rękas
Robert Rejdak

References (48)
  1. Rofagha S, Bhisitkul RB, Boyer DS, et al. SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013; 120(11): 2292–2299.
  2. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014; 98(9): 1144–1167.
  3. Channa R, Sophie R, Bagheri S, et al. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. Am J Ophthalmol. 2015; 159(1): 9–19.e1.
  4. Holz FG, Tadayoni R, Beatty S, et al. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. Eye (Lond). 2016; 30(8): 1063–1071.
  5. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015; 99(2): 220–226.
  6. Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015; 29(6): 721–731.
  7. Framme, C N. Eter, C. Jochmann, H. Schilling, P. Wiedemann, H. Sachs, Z. Hasanbasic, Wachtlin J. PERSEUS 12 month analysis: A Prospective Non-interventional Study to Assess the Effectiveness of Intravitreal Afl ibercept in Routine Clinical Practice in Patients with Wet Age-related Macular Degeneration. 16th EURETINA. ; 2016.
  8. Real Life Use of Intravitreal Aflibercept In France : Observational study in Wet AMD : the RAINBOW study. Association for Research in Vision and Ophthalmology (AVRO), poster 524-A. 0161; 2016.
  9. Wet Age-Related Macular Degeneration. Ophthalmology: Current and Future Developments. 2016: 168–185.
  10. Epstein D, Amrén U. NEAR VISION OUTCOME IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION TREATED WITH AFLIBERCEPT. Retina. 2016; 36(9): 1773–1777.
  11. Lee AY, Lee CS, Egan CA, et al. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. Br J Ophthalmol. 2017 [Epub ahead of print].
  12. Eleftheriadou M, Vazquez-Alfageme C, Citu CM, et al. Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical Setting. Am J Ophthalmol. 2017; 174: 160–168.
  13. Barthelmes D, Nguyen V, Daien V, et al. Fight Retinal Blindness Study Group. TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2017 [Epub ahead of print].
  14. Talks JS, Lotery AJ, Ghanchi F, et al. United Kingdom Aflibercept Users Group. First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. Ophthalmology. 2016; 123(2): 337–343.
  15. Almuhtaseb H, Johnston RL, Talks JS, et al. Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group. Eye (Lond). 2017 [Epub ahead of print].
  16. Kaiser P, Singer M, Tolentino M, et al. Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 2017; 1(4): 304–313.
  17. DeCroos FC, Reed D, Adam MK, et al. Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial. Am J Ophthalmol. 2017; 180: 142–150.
  18. Holz FG, Bandello F, Gillies M, et al. LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013; 97(9): 1161–1167.
  19. Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014; 252(4): 647–655.
  20. Yang Y, Downey L, Mehta H, et al. Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA. Ophthalmol Ther. 2017; 6(1): 175–186.
  21. Silva R, Goncalves C, Meireles A, et al. A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal. Acta Med Port. 2017; 30(6): 449–456.
  22. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014; 121(5): 1092–1101.
  23. Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015; 122(1): 146–152.
  24. Wykoff CC, Croft DE, Brown DM, et al. TREX-AMD Study Group. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmology. 2015; 122(12): 2514–2522.
  25. Chen YN, Powell AM, Mao A, et al. RETROSPECTIVE REVIEW OF LUCENTIS "TREAT AND EXTEND" PATTERNS AND OUTCOMES IN AGE-RELATED MACULAR DEGENERATION. Retina. 2016; 36(2): 272–278.
  26. Ho AC, Busbee BG, Regillo CD, et al. HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014; 121(11): 2181–2192.
  27. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1): 43–58.e1.
  28. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012; 119(6): 1175–1183.
  29. Holz FG, Korobelnik JF, Lanzetta P, et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci. 2010; 51(1): 405–412.
  30. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016; 50: 1–24.
  31. Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond). 2016; 30(2): 270–286.
  32. Holz FG, Tadayoni R, Beatty S, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016; 100(12): 1623–1628.
  33. Huang D, Jia Y, Rispoli M, et al. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TIME COURSE OF CHOROIDAL NEOVASCULARIZATION IN RESPONSE TO ANTI-ANGIOGENIC TREATMENT. Retina. 2015; 35(11): 2260–2264.
  34. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143(4): 566–583.
  35. Waldstein SM, Wright J, Warburton J, et al. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. Ophthalmology. 2016; 123(1): 60–69.
  36. Waldstein SM, Philip AM, Leitner R, et al. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2016; 134(2): 182–190.
  37. Pelosini L, Hull CC, Boyce JF, et al. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci. 2011; 52(5): 2741–2748.
  38. Jaffe GJ, Martin DF, Toth CA, et al. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013; 120(9): 1860–1870.
  39. Dirani A, Ambresin A, Marchionno L, et al. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration. Am J Ophthalmol. 2015; 160(4): 732–8.e2.
  40. Gianniou C, Dirani A, Jang L, et al. REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome. Retina. 2015; 35(6): 1195–1201.
  41. Pokroy R, Mimouni M, Barayev E, et al. PROGNOSTIC VALUE OF SUBRETINAL HYPERREFLECTIVE MATERIAL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB. Retina. 2017 [Epub ahead of print].
  42. Grunwald JE, Pistilli M, Daniel E, et al. Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2017; 124(1): 97–104.
  43. Grunwald JE, Pistilli M, Daniel E, et al. Comparison of Age-Related Macular Degeneration Treatments Trials Research Group, Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015; 122(4): 809–816.
  44. Ying Gs, Kim BJ, Maguire MG, et al. CATT Research Group. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol. 2014; 132(8): 915–921.
  45. Grunwald JE, Daniel E, Huang J, et al. CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 121(1): 150–161.
  46. Coscas F, Coscas G, Lupidi M, et al. Restoration of Outer Retinal Layers After Aflibercept Therapy in Exudative AMD: Prognostic Value. Invest Ophthalmol Vis Sci. 2015; 56(6): 4129–4134.
  47. Schmidt-Erfurth U, Bogunovic H, Sadeghipour A, et al. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 2017.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl